Tesamorelin

Tesamorelin: The Precision Growth Hormone-Releasing Hormone Analog for Metabolic & Lipodystrophy Research ⚖️

Target Visceral Adiposity with a Refined Endocrine Signal. Tesamorelin is not a generic growth hormone secretagogue; it is a synthetically stabilized analog of human growth hormone-releasing hormone (GHRH), featuring a single amino acid substitution (Tyr to D-Ala) for enhanced stability and receptor specificity. As an FDA-approved molecule for reducing excess visceral fat in HIV-associated lipodystrophy, it provides a uniquely relevant and potent tool for researchers investigating the specific metabolic and body composition effects of selectively augmenting the GH/IGF-1 axis. 🔬

Imagine Precisely Elevating the Body's Natural Pulsatile GH to Target Deep Abdominal Fat. Tesamorelin's clinical profile allows you to study a targeted physiological approach to fat metabolism. By stimulating the pituitary to release endogenous growth hormone in a more natural, pulsatile manner, it enables research into the differential reduction of visceral adipose tissue (VAT), improvements in lipid profiles, and potential cognitive benefits without the non-physiological continuous exposure of direct GH administration. This makes it a critical compound for modeling HIV-associated and non-HIV metabolic dysfunction, NAFLD/NASH progression, and age-related changes in body composition.

Clinical-Translation Research Demands Pharmaceutical-Grade Fidelity. Working with a molecule that has an established human pharmacopoeia requires material of the highest reference standard.

• Pharmaceutical-Standard Purity: ≥98% purity, with the precise sequence D-Alaninamide, L-alanyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-α-glutamyl-L-α-aspartyl-L-alanyl-D-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-leucyl-L-seryl-L-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutaminyl-L-leucyl-L-seryl-L-arginyl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-argininamide verified by advanced analytical methods (HPLC, MS). ✅

• Comprehensive Regulatory-Grade Documentation: Full batch-specific Certificate of Analysis (CoA) with detailed impurity profiling, supporting preclinical and translational study protocols. 📄

• Optimized for Metabolic Phenotyping Studies: Supplied as a stable, lyophilized powder ideal for chronic dosing in models of metabolic syndrome and lipodystrophy. ⚙️

Your Strategic Partner in Metabolic Pharmacology Development.
Translating an approved endocrine therapy into novel research insights requires a partner with precision and regulatory awareness. We provide confidential synthesis, scale-flexible quantities, and documentation aligned with research-grade standards to empower your studies from mechanism exploration to proof-of-concept. Partner with us to investigate the precise modulation of growth hormone for metabolic health. 🚀

Technical Specifications:

• Primary Mechanism: Stabilized GHRH analog (D-Ala substitution) for selective stimulation of endogenous GH release.

• Core Research Application: Preclinical models of visceral adiposity (HIV-associated and metabolic syndrome), dyslipidemia, NAFLD, and related cognitive dysfunction.

• Appearance: White to off-white lyophilized powder.

• Research Value: The definitive targeted GHRH analog for research into the selective reduction of visceral fat and associated metabolic derangements. 🎯